5-HT1A-mediated promotion of mitogen-activated T and B cell survival and proliferation is associated with increased translocation of NF-κB to the nucleus

Brain, Behavior, and Immunity

Volumn 18, Issue 1, 2004, Pages 24-34

  Abdouh, Mohamed ^a,b,c   Albert, Paul R ^d   Drobetsky, Elliot ^a   Filep, János G ^a,c   Kouassi, Edouard ^a,b,c  

^a MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^b INRS INSTITUT ARMAND FRAPPIER   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

5 HT1A receptor; Apoptosis; Cell survival and proliferation; NF B; Psychoneuroimmunology; Serotonin

Indexed keywords

DNA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGENIC AGENT; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NUCLEAR PROTEIN; PROTEIN SUBUNIT; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; PIPERAZINE DERIVATIVE; PYRIDINE DERIVATIVE; SEROTONIN AGONIST;

ANIMAL CELL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CELL CYCLE S PHASE; CELL DEATH; CELL NUCLEUS; CELL PROLIFERATION; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; DIPLOIDY; DNA CLEAVAGE; DNA CONTENT; FEMALE; GENE TRANSLOCATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; DRUG EFFECT; LYMPHOCYTE ACTIVATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; B-LYMPHOCYTES; CELL DIVISION; CELL NUCLEUS; CELL SURVIVAL; FEMALE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MITOGENS; NF-KAPPA B; PIPERAZINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TRANSLOCATION, GENETIC;

EID: 0345687972     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-1591(03)00088-6     Document Type: Article

References (50)

1. Adayev T., El-Sherif Y., Barua M., Penington N.J., Banerjee P. Agonist stimulation of the serotonin1A receptor causes suppression of anoxia-induced apoptosis via mitogen-activated protein kinase in neuronal HN2-5 cells. J. Neurochem. 72:1999;1489-1496.
2. 1A receptor mRNA and protein in activated B and T lymphocytes. J. Biol. Chem. 276:2001;4382-4388.
3. Ader R., Cohen N., Felten D. Psychoneuroimmunology: interactions between the nervous system and the immune system. Lancet. 345:1995;99-103.
4. 1A receptor inhibits apoptosis induced by serum deprivation in cultured neurons from chick embryo. Brain Res. 777:1997;179-186.
5. Aune T.M., Golden H.W., McGrath K.M. Inhibitors of serotonin synthesis and antagonists of serotonin 1A receptors inhibit T lymphocyte function in vitro and cell-mediated immunity in vivo. J. Immunol. 153:1994;489-498.
6. Aune T.M., McGrath K.M., Sarr T., Bombara M.P., Kelley K.A. Expression of 5HT1a receptors on activated human T cells. Regulation of cyclic AMP levels and T cell proliferation by 5-hydroxytryptamine. J. Immunol. 151:1993;1175-1183.
7. Baeuerle P.A., Henkel T. Function and activation of NF-kappa B in the immune system. Annu. Rev. Immunol. 12:1994;141-179.
8. Baldwin A.S. Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 14:1996;649-683.
9. Barker K.S., Davis A.T., Li B., Rollins-Smith L.A. In vitro studies of spontaneous and corticosteroid-induced apoptosis of lymphocyte populations from metamorphosing frogs/RU486 inhibition. Brain Behav. Immun. 11:1997;119-131.
10. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-κB transcription factors. Oncogene. 18:1999;6910-6924.
11. Barnes P.J., Karin M. Nuclear factor-κB: a pivotal transcription factor in chronic inflammatory diseases. N. Engl. J. Med. 336:1997;1066-1071.
12. Bellinger D.L., Felten S.Y., Felten D.L. Maintenance of noradrenergic sympathetic innervation in the involuted thymus of the aged Fischer 344 rat. Brain Behav. Immun. 2:1988;133-150.
13. Benedict C.R., Mathew B., Rex K.A., Cartwright J. Jr., Sordahl L.A. Correlation of plasma serotonin changes with platelet aggregation in an in vivo dog model of spontaneous occlusive coronary thrombus formation. Circ. Res. 58:1986;58-67.
14. Blier P., de Montigny C., Chaput Y. Modifications of the serotonin system by antidepressant treatments; implication for the therapeutic response in major depression. J. Clin. Psychopharmacol. 7:1987;24S-35S.
15. 1A receptor agonists as neuroprotective agents in cerebral ischemia. Krieglstein J., Oberpichler H. Pharmacology of Cerebral Ischemia. 1990;485-491 Wissensch. Verlag, Stuttgart.
16. Charney D.S., Krystal J.H., Delgado P.L., Heninger G.R. Serotonin-specific drugs for anxiety and depressive disorders. Annu. Rev. Med. 41:1990;437-446.
17. Chen F., Castranova V., Shi X. New insights into the role of nuclear factor-kappaB in cell growth regulation. Am. J. Pathol. 159:2001;387-397.
18. Cohen R.A. Platelet-induced neurogenic coronary contractions due to accumulation of the false 5-hydroxytryptamine. J. Clin. Invest. 75:1985;286-292.
19. 1A receptor-mediated increase in receptor expression and activation of nuclear factor-κ B in transfected Chinese hamster ovary cells. Mol. Pharmacol. 52:1997;221-226.
20. Crivellato E., Damiani D., Mallardi F., Travan L. Suggestive evidence for a microanatomical relationship between mast cells and nerve fibres containing substance P, calcitonin gene related peptide, vasoactive intestinal polypeptide, and somatostatin in the rat mesentery. Acta Anat. (Basel). 141:1991;127-131.
21. Endo Y., Shibazaki M., Nakamura M., Takada H. Contrasting effects of lipopolysaccharides (endotoxins) from oral black-pigmented bacteria and Enterobacteriaceae on platelets, a major source of serotonin, and on histamine-forming enzyme in mice. J. Infect. Dis. 175:1997;1404-1412.
22. Essman W.B. Serotonin distribution in tissues and fluids. Essman W.B. Serotonin in Health and Disease, vol. I: Availability, Localization and Disposition. 1978;15-179 Spectrum Publications, New York.
23. Eugen-Olsen J., Afzelius P., Andresen L., Iversen J., Kronborg G., Aabech P., Nielsen J.O., Hofmann B. Serotonin modulates immune function in T cells from HIV-seropositive subjects. Clin. Immunol. Immunopathol. 84:1997;115-121.
24. Foulds S. Novel flow cytometric method for quantifying nuclear binding of the transcription factor nuclear factor kappa B in unseparated human monocytes and polymorphonuclear cells. Cytometry. 29:1997;182-186.
25. 1A receptors mediate pindobind suppression of natural killer cell activity: modulation by catalase. Int. Immunopharmacol. 1:2001;247-253.
26. Freire-Garabal M., Nunez-Iglesias M.J., Balboa J.L., Fernandez-Rial J.C., Rey-Mendez M. Effects of buspirone on the immune response to stress in mice. Pharmacol. Biochem. Behav. 51:1995;821-825.
27. Gerondakis S., Grumont R., Rourke I., Grossmann M. The regulation and roles of Rel/NF-kappa B transcription factors during lymphocyte activation. Curr. Opin. Immunol. 10:1998;353-359.
28. Ghosh S., May M.J., Kopp E.B. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16:1998;225-260.
29. Grumont R.J., Rourke I.J., O'Reilly L.A., Strasser A., Miyake K., Sha W., Gerondakis S. B lymphocytes differentially use the Rel and nuclear factor kappaB1 (NF-kappaB1) transcription factors to regulate cell cycle progression and apoptosis in quiescent and mitogen-activated cells. J. Exp. Med. 187:1998;663-674.
30. Hellstrand K., Hermodsson S. Serotoninergic 5-HT1a receptors regulate a cell contact mediated interaction between natural killer cells and monocytes. Scand. J. Immunol. 37:1993;7-18.
31. 1A receptors. Cell. Immunol. 163:1995;1-9.
32. Junod A.F. Uptake, metabolism and efflux of 14 C-5-hydroxytryptamine in isolated perfused rat lungs. J. Pharmacol. Exp. Ther. 183:1972;341-355.
33. Karin M. The NF-κB activation pathways: its regulation and role in inflammation and cell survival. Cancer J. 4(Suppl. 1):1998;S92-S99.
34. Karin M. How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene. 18:1999;6867-6874.
35. Karin M., Cao Y., Greten F.R., Li Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer. 2:2002;301-310.
36. Karin M., Lin A. NF-kappaB at the crossroads of life and death. Nat. Immunol. 3:2002;221-227.
37. Krishan A. Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J. Cell Biol. 66:1975;188-193.
38. Liu J., Lauder J.M. Serotonin and nialamide differentially regulate survival and growth of cultured serotonin and catecholamine neurons. Dev. Brain Res. 60:1991;59-67.
39. Mössner R., Lesch K.P. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav. Immun. 12:1998;249-271.
40. Nagabhushan M., Mathews H.L., Witek-Janusek L. Aberrant nuclear expression of AP-1 and NFkappaB in lymphocytes of women stressed by the experience of breast biopsy. Brain Behav. Immun. 15:2001;78-84.
41. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods. 139:1991;271-279.
42. Olivier B., Soudijn W., van Wijngaarden I. The 5-HT1A receptor and its ligands: structure and function. Prog. Drug Res. 52:1999;103-165.
43. Palayoor S.T., Macklis R.M., Bump E.A., Coleman C.N. Modulation of radiation-induced apoptosis and G2/M block in murine T-lymphoma cells. Radiat. Res. 141:1995;235-243.
44. 1A receptor in rat brain: correlation with receptor binding. J. Neurosci. 12:1992;440-453.
45. Prehn J.H., Welsch M., Backhauss C., Nuglisch J., Ausmeier F., Karkoutly C., Krieglstein J. Effects of serotoninergic drugs in experimental brain ischemia: evidence for a protective role of serotonin in cerebral ischemia. Brain Res. 630:1993;110-120.
46. 1A receptor agonists on septal cholinergic neurons in culture. Dev. Brain Res. 82:1994;245-258.
47. Saxena P.R. Serotonin receptors: subtypes, functional responses and therapeutic relevance. Pharmacol. Ther. 66:1995;339-368.
48. Timmons S., Huzoor-Akbar, Grabarek J., Kloczewiak M., Hawiger J. Mechanism of human platelet activation by endotoxic glycolipid-bearing mutant Re595 of Salmonella minnesota. Blood. 68:1986;1015-1023.
49. Törk I. Anatomy of the serotoninergic system. Ann. N. Y. Acad. Sci. 600:1990;9-35.
50. 3H]5-hydroxytryptamine in saphenous veins and cerebral arteries of the dog. J. Pharmacol. Exp. Ther. 226:1983;579-588.